| __timestamp | Amphastar Pharmaceuticals, Inc. | Bio-Techne Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 60716000 |
| Thursday, January 1, 2015 | 46974000 | 119401000 |
| Friday, January 1, 2016 | 47298000 | 140879000 |
| Sunday, January 1, 2017 | 50918000 | 199243000 |
| Monday, January 1, 2018 | 58044000 | 240636000 |
| Tuesday, January 1, 2019 | 63109000 | 264359000 |
| Wednesday, January 1, 2020 | 65157000 | 260583000 |
| Friday, January 1, 2021 | 68920000 | 324951000 |
| Saturday, January 1, 2022 | 66592000 | 372766000 |
| Sunday, January 1, 2023 | 80393000 | 378378000 |
| Monday, January 1, 2024 | 396826000 |
Igniting the spark of knowledge
In the ever-evolving biotech industry, operational efficiency is key to sustaining growth. Over the past decade, Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Bio-Techne's SG&A expenses surged by over 500%, peaking at nearly $380 million in 2023. This reflects their aggressive expansion and investment in innovation. In contrast, Amphastar's SG&A expenses grew by approximately 100%, reaching $80 million in 2023, indicating a more conservative approach. Notably, Bio-Techne's expenses consistently outpaced Amphastar's, highlighting their differing strategic priorities. The data for 2024 is incomplete, suggesting potential shifts in these trends. As the biotech landscape continues to evolve, these companies' financial strategies will be pivotal in shaping their future trajectories.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Bio-Techne Corporation
Novo Nordisk A/S vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Amgen Inc. vs Amphastar Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Genmab A/S vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Blueprint Medicines Corporation
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Catalyst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Amphastar Pharmaceuticals, Inc.
Opthea Limited or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Amphastar Pharmaceuticals, Inc. and Xencor, Inc.: SG&A Spending Patterns Compared